However, multiple questions remain to determine how to incorporate the treatment of HER2-low breast cancer in the rapidly evolving treatment landscape of the traditionally known hormone receptor-positive and triple-negative breast cancers. Here, ERBB2 is linked to triple-negative breast carcinoma.